George Georgiou serves as Executive at Aeglea BioTherapeutics, Inc., where they oversee executive responsibilities. Since joining the company, George Georgiou has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Aug 13, 2018 involved exercising options for 20,000 shares valued at $94.6K.
George Georgiou currently holds 175,861 shares of Aeglea BioTherapeutics, Inc. (AGLE), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, George Georgiou has been a net neutral trader of AGLE stock. They have purchased $0 and sold $0 worth of shares.
George Georgiou's most recent insider trade was on Aug 13, 2018, when they sold 20,000 shares at $4.73 per share.
Get notified when new Form 4 filings are submitted
| 17,333 |
| $7.28 |
| Discretionary |